RJA
GSK icon

Raymond James & Associates’s GSK GSK Stock Holding History

Raymond James & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,040
Closed -$6K – 4044
2020
Q4 		$6K Buy
+9,040
New +$415K ﹤0.01% 3738

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's GSK Position: Q3 2024 in Review

Raymond James & Associates reduced its GSK (GSK) stake by 2.1% in Q3 2024, selling an estimated $981K and leaving 1,141,789 shares worth $46.7M. The position accounts for 0.03% of the portfolio, ranked #463.

Raymond James & Associates first reported a position in GSK in Q2 2013 and has held it in 46 quarters since. The position peaked at $174M in Q3 2017. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

  • Raymond James & Associates held 1,141,789 shares of GSK worth $46.7M as of Q3 2024.
  • Raymond James & Associates sold 23,983 GSK shares in Q3 2024, an estimated $981K.
  • GSK made up 0.03% of Raymond James & Associates's portfolio in Q3 2024, its #463 holding.
  • Raymond James & Associates first reported a position in GSK in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's GSK position peaked at $174M in Q3 2017.
  • 899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.